Integrin alpha V beta 8

Integrin alpha V beta 8 Overview

English Nameintegrin alpha V/beta 8Approved Drugs0
Drugs in Clinical Trials2Target Synonymalphavbeta8 integrin
Highest Development StagePhase 2 Clinical
English Nameintegrin alpha V/beta 8
Target Synonymalphavbeta8 integrin
Approved Drugs0
Drugs in Clinical Trials2
Highest Development StagePhase 2 Clinical

Integrin alpha V beta 8 Background

Integrin alpha V beta 8 (ITGAV & ITGB8 or ITGAVB8) is expressed in yolk sac, placenta, brain perivascular astrocytes, Schwann cells, renal glomerular mesangial cells and pulmonary epithelial cells. Unlike other alpha V integrins, ITGAVB8 does not appear to assume different activation states, and the cytoplasmic tail does not connect to the cytoskeleton. It binds ligands containing an RGD motif, including vitronectin, fibrin and the latency associated peptide (LAP) of the latent TGF-beta complex. High affinity binding of alpha V beta 8 to LAP allows proteolytic cleavage by MT1-MMP, which releases active TGF-beta. This mechanism differs from that of alpha V beta 6, the other alpha V integrin which can activate TGF-beta from latency through non-proteolytic mechanisms. Downstream effects of TGF-beta activation include control of cell growth and associated vascularization.

Integrin alpha V beta 8 Synonyms

Integrin alpha V beta 8,ITGAV&ITGB8

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
NesvategrastOTT-166(OcuTerra Therapeutics); SF-0166Phase 2 ClinicalScifluor Life Sciences Inc, OcuTerra Therapeutics IncDiabetic macular oedema; Diabetic Retinopathy; Macular Degeneration
Details
CRB-601CRB-601Phase 2 ClinicalUc San Francisco, Corbus Pharmaceuticals Holdings IncSolid tumours
Details
  • Overview
  • Product List
  • Clinical Drug Information